GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merus Labs International Inc (NAS:MSLI) » Definitions » EV-to-EBITDA

Merus Labs International (Merus Labs International) EV-to-EBITDA : 6.02 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Merus Labs International EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Merus Labs International's enterprise value is $152.23 Mil. Merus Labs International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2017 was $25.31 Mil. Therefore, Merus Labs International's EV-to-EBITDA for today is 6.02.

The historical rank and industry rank for Merus Labs International's EV-to-EBITDA or its related term are showing as below:

MSLI's EV-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 14.03
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Merus Labs International's stock price is $1.30. Merus Labs International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2017 was $-0.075. Therefore, Merus Labs International's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Merus Labs International EV-to-EBITDA Historical Data

The historical data trend for Merus Labs International's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus Labs International EV-to-EBITDA Chart

Merus Labs International Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.31 5.38 22.43 6.77 8.71

Merus Labs International Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.96 11.49 8.71 8.49 8.41

Competitive Comparison of Merus Labs International's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Merus Labs International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus Labs International's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merus Labs International's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Merus Labs International's EV-to-EBITDA falls into.



Merus Labs International EV-to-EBITDA Calculation

Merus Labs International's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=152.230/25.306
=6.02

Merus Labs International's current Enterprise Value is $152.23 Mil.
Merus Labs International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merus Labs International  (NAS:MSLI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Merus Labs International's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.30/-0.075
=At Loss

Merus Labs International's share price for today is $1.30.
Merus Labs International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.075.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Merus Labs International EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Merus Labs International's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus Labs International (Merus Labs International) Business Description

Traded in Other Exchanges
N/A
Address
Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Merus Labs International (Merus Labs International) Headlines